Histogen Inc logo

HSTO - Histogen Inc News Story

$0.715 -0.0  -0.0%

Last Trade - 9:00pm

Micro Cap
Market Cap £21.7m
Enterprise Value £4.17m
Revenue £1.02m
Position in Universe 6367th / 7243

Histogen and Amerimmune Enter into a Collaborative Development and Commercialization Agreement for Emricasan in the Treatment of COVID-19

Tue 27th October, 2020 12:00pm
For best results when printing this announcement, please click on link below:

Histogen Receives IND Approval from FDA to Initiate a Phase 1 Study of
Emricasan in Mild-COVID-19 Patients to Assess Safety and Tolerability

Amerimmune to Lead Development Efforts of Emricasan in a Phase 1 Study in
Mild-COVID-19 Patients Expected to Commence as Early as the End of 2020

SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a
clinical-stage therapeutics company focused on developing potential
first-in-class therapeutics that ignite the body’s natural process to repair
and maintain healthy biological function, today announced entering into a
Collaborative Development and Commercialization Agreement with Amerimmune LLC
to jointly develop emricasan, an orally active caspase inhibitor, for the
treatment of COVID-19. Additionally, Histogen has received Investigational New
Drug (IND) approval from the United States Food and Drug Administration (FDA)
to initiate a Phase 1 study of emricasan in mild-COVID-19 patients to assess
safety and tolerability. Amerimmune, which will lead the development efforts
of emricasan, has selected clinical sites at two major medical centers in the
New York City metropolitan area to conduct the study. Amerimmune is pursuing
non-dilutive funding in order to support the clinical program and anticipates
initiating the Phase 1 study as early as the end of 2020.

Under the terms of the collaboration, Histogen will retain ownership and
oversight over emricasan and responsibility for all regulatory filings and
maintaining its existing caspase inhibitor patent portfolio. Amerimmune, in
collaboration with Histogen, will fund and lead the emricasan development
efforts and maintain its own portfolio of patents for caspase inhibition and
immunotherapy. Additionally, Amerimmune has been granted an option to
commercialize emricasan under certain conditions for the sole purpose of
supporting future third-party partnering transactions. Should any such
partnering transaction emerge, Histogen and Amerimmune will share profits
equally. The parties will manage the collaboration under a joint development
and partnering committee governance structure.  

“Since completing the merger with Conatus Pharmaceuticals in the second
quarter, we have been evaluating opportunities to create value from the
emricasan asset, which we believe can be best accomplished in partnership with
Amerimmune in the potential treatment of COVID-19. The Amerimmune team brings
both a strong caspase inhibitor scientific background and relevant
technologies for the treatment of COVID-19 using caspase inhibitors to this
collaboration,” said Richard Pascoe, President and CEO of Histogen. “With
Amerimmune leading the development efforts related to emricasan, Histogen will
remain focused on delivering the top line data results in the fourth quarter
of 2020 for its HST-001 Phase 1b/2a trial for androgenic alopecia in men,
evaluating a clinical pathway for HST-002 as a dermal filler, and continuing
to progress our HST-003 program for regeneration of cartilage in the knee,”
concluded Pascoe.

“We are delighted to work in collaboration with Histogen to explore the
potential role of caspase inhibition as a therapy for reducing disease
severity and progression of COVID-19,” said Dr. Oral Alpan, CEO of
Amerimmune. “We believe our research and development efforts over the last
decade have enabled us to make important advancements in our understanding of
how SARS-CoV-2 compromises the immune system. We are encouraged by our
progress and look forward to advancing emricasan into the clinic as early as
the end of 2020,“ concluded Dr. Alpan.    

About Emricasan
Emricasan is a first-in-class, orally active, pan-caspase inhibitor designed
to reduce the activity of enzymes that mediate inflammation and apoptosis.
Histogen believes that by reducing the activity of these enzymes, caspase
inhibitors have the potential to interrupt the progression of a variety of
diseases.   To date, emricasan has been studied in over 950 patients in 19
completed clinical trials across a broad range of liver diseases. In NASH
cirrhosis patients in multiple clinical Phase II trials conducted by Conatus,
emricasan demonstrated rapid and sustained reductions in elevated levels of
key biomarkers of inflammation and cell death. Similarly, elevated biomarkers
are also believed to play a role in the severity and progression of COVID-19.

About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing
potential first-in-class restorative therapeutics that ignite the body’s
natural process to repair and maintain healthy biological function.
Histogen’s innovative technology platform utilizes cell conditioned media
and extracellular matrix materials produced by hypoxia-induced multipotent
cells. Histogen’s proprietary, reproducible manufacturing process provides
targeted solutions across a broad range of therapeutic indications including
hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk
repair. For more information, please visit www.histogen.com.

About Amerimmune
Amerimmune LLC is a research center and immunology laboratory with a strong
focus on identifying underlying mechanisms of immune disorders. Amerimmune’s
mission is to bring relevant science, data, and diagnostic and therapeutic
solutions to diseases that involve the immune system. Amerimmune LLC is a
spinoff of Amerimmune Diagnostics LLC, which is focused on establishing a
network of physician-owned immunology labs across the United States.
Amerimmune Diagnostics’ clinical approach led to the development of the
innovative therapeutics technology upon which Amerimmune was founded. When the
COVID-19 pandemic emerged early this year, Amerimmune brought its expertise to
bear against this devastating disease. Amerimmune is a privately held
development-stage company based in Fairfax, VA. For more information and to
explore partnering opportunities, please visit www.amerimmune.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform
Act of 1995 and other Federal securities laws. For example, we are using
forward-looking statements when we discuss our future operations and our
ability to successfully initiate and complete clinical trials, obtain clinical
trial data and achieve regulatory milestones and related timing, including
those related to the planned Phase 1 study of emricasan for the treatment of
COVID-19; the nature, strategy and focus of our business; the sufficiency of
our and Amerimmune’s cash resources and ability to commence the planned
Phase 1 study of emricasan and achieve value for our stockholders; and the
development and commercial potential and potential benefits of any of our
product candidates and the Collaborative Development and Commercialization
Agreement with Amerimmune or any other collaboration agreements. We may not
actually achieve the plans, carry out the intentions or meet the expectations
or projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Because such
statements deal with future events and are based on our current expectations,
they are subject to various risks and uncertainties and actual results,
performance or achievements of ours that could differ materially from those
described in or implied by the statements in this press release, including:
the uncertainties associated with the clinical development and regulatory
approval of our product candidates and Amerimmune’s ability to further
develop emricasan for the treatment of COVID-19, including the complexity and
length of studies required to commercialize emricasan for COVID-19 and
potential delays in the commencement, enrollment, and completion of clinical
trials, such as the planned emricasan Phase 1 study for the treatment of
COVID-19; the uncertainties associated with Amerimmune’s pursuit and receipt
of non-dilutive capital for the advancement of emricasan, including any
potential government grants; Histogen’s dependence on its collaboration
partner, Amerimmune, to carry out the development of emricasan and the
potential for delays in the timing of regulatory approval; competition in the
COVID-19 market and other markets in which Histogen and its collaboration
partner operate; risks related to business interruptions to Histogen and/or
Amerimmune, including the outbreak of COVID-19 coronavirus, which could
seriously harm our respective financial conditions and increase our respective
costs and expenses; the potential for adverse reactions to emricasan; and
market conditions. The foregoing review of important factors that could cause
actual events to differ from expectations should not be construed as
exhaustive and should be read in conjunction with statements that are included
herein and elsewhere, including those risks discussed in our filings with the
Securities and Exchange Commission. Except as otherwise required by law, we
disclaim any intention or obligation to update or revise any forward-looking
statements, which speak only as of the date hereof, whether as a result of new
information, future events, or circumstances or otherwise.


Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.